Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Notes Payables: 2021

  • ARS Pharmaceuticals' Notes Payables was N/A to $3.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was $3.5 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q4 2021, ARS Pharmaceuticals' Notes Payables is $3.5 million.
  • ARS Pharmaceuticals' Notes Payables' 5-year high stood at $3.5 million during Q4 2021, with a 5-year trough of $3.5 million in Q4 2021.
  • For the 1-year period, ARS Pharmaceuticals' Notes Payables averaged around $3.5 million, with its median value being $3.5 million (2021).